

3 More EU Countries Hit Pause on AstraZeneca After Reports of Illness and Deaths

Denmark, Norway and Iceland today joined other EU countries in suspending use of the AstraZeneca-Oxford vaccine following reports of blood clots and the death of a 60-year-old woman in Denmark.

By [Megan Redshaw](#)

Global Research, March 12, 2021

[Children's Health Defense](#) 11 March 2021

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles **can be read in 27 languages by activating the “Translate Website”** drop down menu on the top banner of our home page (Desktop version).

Denmark, Norway and Iceland today [announced](#) they are joining other European countries in temporarily suspending use of the [AstraZeneca-Oxford](#) COVID vaccine following reports of blood clots in people who got the vaccine.

Denmark suspended the shots until further notice after a 60-year-old woman died from a blood clot which formed after she was vaccinated, [reported Reuters](#).

The Danish decision came days after Austrian [authorities announced](#) they were suspending a batch of AstraZeneca’s COVID vaccine while investigating the death of one person and the illness of another after receiving the shots. The same batch used in Austria was used in Denmark, [according to Reuters](#).

In Austria, a 49-year-old woman died of severe coagulation disorders, and a 35-year-old woman developed a pulmonary embolism -- an acute lung disease caused by a dislodged blood clot -- and is recovering, said [The Federal Office for Safety in Health Care](#) (BASG) in Austria.

Austrian newspaper *Niederösterreichische Nachrichten*, broadcaster ORF and the APA news agency [reported](#) that both women were nurses at the same clinic where the vaccine batch was used.

In a [statement](#) provided to Reuters, AstraZeneca said the safety of its vaccine had been extensively studied in human trials and that peer-reviewed data had confirmed the vaccine was generally well tolerated.

Earlier this week, AstraZeneca [reported](#) “no confirmed serious adverse events associated with the vaccine” during trials and said it was working with Austria in its investigation.

Estonia, Latvia, Lithuania and Luxembourg have suspended all or part of their AstraZeneca vaccine roll-out as a precaution while they investigate concerns related to blood clots, [reported France 24](#).

[According to Reuters](#), Italy announced it banned a batch of the AstraZeneca COVID vaccine following the deaths of two men who had recently been vaccinated. One man was a 43-year-old naval officer who died after a suspected heart attack the day after his shot. The second man, a 50-year-old policeman, fell ill within 24 hours of his injection, never recovered and died 12 days after being vaccinated. Both men had received shots from AstraZeneca's ABV2856 batch.

As of March 10, 30 cases of [thromboembolic events had been reported](#) to [EudraVigilance](#), the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or are being studied in [clinical trials](#) in the European Economic Area.

As [The Defender reported](#) today, 12 prominent doctors and scientists are demanding that EU regulators address seven critical safety issues relating to the AstraZeneca, Pfizer and Moderna COVID vaccines, or withdraw approval of the vaccines for use in the EU.

The UK government is meanwhile urging people to "still go and get their COVID-19 vaccine," stressing the suspension in multiple countries "is a precautionary measure," [reported EuroNews](#).

The [UK's Medicines and Healthcare Products Regulatory Agency](#) also urged people to still get vaccinated, as it [had not been confirmed](#) that the COVID vaccine caused the blood clot in the woman in Denmark.

On March 2, [The Defender reported](#) that government data showed 43% more reports of injuries related to the AstraZeneca-Oxford vaccine in the UK, including 77% more adverse events and 25% more deaths compared to the [Pfizer-BioNTech](#) vaccine.

Britain's regulator, the [Medicines and Healthcare Products Regulatory Agency](#) (MHRA), runs YellowCard, which is the nearest British equivalent to the [Vaccine Adverse Events Reporting System](#) or VAERS in the U.S.

The MHRA [expressed](#) no concern about the number of reports of adverse events connected with AstraZeneca's COVID vaccine.

"The problem with spontaneous reports of suspected adverse reactions to a vaccine are the [enormous difficulty](#) of distinguishing a causal effect from a coincidence," **Stephen Evans**, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine [told France 24](#).

Last month two regions in Sweden temporarily halted AstraZeneca COVID vaccinations after 400 people received the vaccine and 100 people experienced adverse reactions leaving them unable to work. Another region observed a surprising number of side effects after a mass vaccination effort of more than 500 people, [reported The Defender](#).

South Africa halted the roll-out of AstraZeneca's COVID vaccine due to low efficacy in February, and European countries France, Germany and Sweden [reported](#) more side effects from the AstraZeneca COVID vaccine than from the Pfizer-BioNTech vaccine.

The [World Health Organization](#) approved the AstraZeneca-Oxford COVID vaccine for emergency use last month, despite growing safety concerns in other countries and

[questionable](#) clinical trials.

AstraZeneca's COVID vaccine has not yet been approved for use in the U.S. but the drugmaker plans to file for [Emergency Use Authorization](#) with the U.S Food and Drug Administration in the upcoming weeks pending the results of a clinical trial, [according to CBS News](#).

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

***Megan Redshaw** is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.*

Featured image is from Children's Health Defense

The original source of this article is [Children's Health Defense](#)
Copyright © [Megan Redshaw](#), [Children's Health Defense](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Megan Redshaw](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca